Search
Returning search results with filters:
Remove filter for
Audience: Health professionals
Remove filter for
Category: Drugs
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Recall class
Displaying 1 - 15 of 448 items.
Importation of Italian-authorized Cisatracurio Hikma 2 mg/mL Ampoules due to the Current Shortage of Canadian-authorized Cisatracurium Omega
AlertHealth professional risk communication | 2024-04-24
Ezetrol (ezetimibe) and the Risks of Drug-Induced Liver Injury and Severe Cutaneous Adverse Reactions
AlertHealth professional risk communication | 2024-03-27
Shortage of Nitroglycerin Sprays and Tablets in Canada
AlertPublic advisory | 2023-11-10
Importation of UK-Authorized Potassium Chloride 15% w/v Concentrate for Solution for Infusion due to shortage of Canadian-authorized Potassium Chloride for Injection Concentrate
AlertHealth professional risk communication | 2023-10-24
IDHIFA (enasidenib mesylate) – Market Withdrawal and Continued Access
AlertHealth professional risk communication | 2023-06-08
ISTODAX (romidepsin) – Restricted Access Program
AlertHealth professional risk communication | 2023-03-20
ZEJULA (niraparib) - Update on the Maintenance Treatment in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in the Second or Later Line Setting
AlertHealth professional risk communication | 2023-02-16
RUZURGI (amifampridine) - Authorization Status
AlertHealth professional risk communication | 2023-01-20
OCALIVA (obeticholic acid) – New Contraindication for the Treatment of Primary Biliary Cholangitis (PBC)
AlertHealth professional risk communication | 2022-12-05
Privigen: Series of adverse reactions
RecallHealth product recall | 2022-12-01
Canadian labelling for all JAK inhibitors to include risks of serious heart-related problems, fatal blood clots and cancer
AlertPublic advisory | 2022-11-01
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
AlertHealth professional risk communication | 2022-10-31
IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure
AlertHealth professional risk communication | 2022-08-29
PMS-Hydromorphone: Affected lot may contain tablets that could potentially lead to overdose
RecallHealth product recall | 2022-08-22
Recall of one lot of pms-Hydromorphone due to packaging error that could potentially lead to overdose
AlertPublic advisory | 2022-08-20